Latest news for  (IMPNF) Stock

Imperial Mining Group Ltd Ordinary Shares

Guggenheim analyst Yige Guo downgrades Boundless Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLD#NASDAQ">BOLD</a>) from Buy to Neutral.

News

Downgrades

Analyst Ratings

BOLD

Guggenheim Downgrades Boundless Bio to Neutral

JP Morgan analyst Michael Rehaut maintains Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) with a Neutral and lowers the price target from $192 to $173.

Price Target

JP Morgan Maintains Neutral on Lennar, Lowers Price Target to $173

WIIM

LDTC

LeddarTech shares are trading higher after the company announced it received the first installment of the TI pre-paid royalty fee.

NYXH

Nyxoah shares are trading higher after the company announced its Genio Neuromodulation therapy debuted in England at UCLH under NHS coverage.

Susquehanna analyst Christopher Rolland maintains Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) with a Positive and raises the price target from $200 to $225.

AVGO

Susquehanna Maintains Positive on Broadcom, Raises Price Target to $225

JP Morgan analyst Michael Rehaut maintains KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) with a Neutral and lowers the price target from $92.5 to $82.

JP Morgan Maintains Neutral on KB Home, Lowers Price Target to $82

Inovio Pharmaceuticals shares are trading lower after the company announced a public offering of 10 million shares for gross proceeds of $30 million.

Stifel analyst Benjamin Burnett maintains Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) with a Buy and lowers the price target from $9 to $4.

RPTX

Stifel Maintains Buy on Repare Therapeutics, Lowers Price Target to $4

On Thursday, Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) CFO&nbsp;Dave Zinsner&nbsp;did not rule out the possibility of splitting <a target="_blank" href="https://www.benzinga.com/topic/intel" rel="noreferrer noopener">the company&#8217;s factory and</a> product-development divisions as the next CEO takes charge, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-12-12/intel-says-the-idea-of-splitting-up-company-is-an-open-question?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">cites</a> from Barclays technology conference in San Francisco.
Zinsner is also serving as Intel&#8217;s interim co-CEO along with&nbsp;Michelle Johnston Holthaus following Pat Gelsinger&#8217;s exit after he failed to impress the board with his turnaround efforts.
Intel&nbsp;stock plunged 57% year-to-date as it failed to tap the current enterprise customer shift to artificial intelligence technology, which contributed to the upside for Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>). Taiwan Semiconductor stock is up 89% year-to-date.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42470137/t-mobiles-premium-valuation-prompts-downgrade-growth-projections-decelerate" rel="noreferrer noopener">T-Mobile&#8217;s Premium Valuation Prompts Downgrade As Growth Projections Decelerate: Analyst</a>
Intel also failed to boost its artificial intelligence accelerator chip business as its Gaudi chip could not gain traction in a market led by Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>). Nvidia stock is up over 185% year-to-date.
Zinsner&nbsp;said during the conference that Intel&#8217;s two divisions were already separate in terms of their operating structure, which is in sharp contrast to Gelsinger&#8217;s plans to maintain the two units together.
The co-CEOS stressed during the conference that it would take time to fix Intel&#8217;s moat. They flagged challenges regarding data center products and outsourcing of contract manufacturing efforts.
Holthaus said that Intel will focus on updating generic graphics-chip offerings to make them competitive. In 2025, Intel will focus on containing Intel&#8217;s market-share loss, as per Holthaus.
The co-CEOs hinted at a possible&nbsp;sale of Intel&#8217;s manufacturing operations lest the new chipmaking technology fails to gain traction, Reuters cites from the conference.
During Taiwan Semiconductor founder Morris Chang&#8217;s autobiography launch, he highlighted <a target="_blank" href="https://www.benzinga.com/24/12/42435733/taiwan-semi-founder-calls-for-new-strategy-after-intel-chiefs-departure" rel="noreferrer noopener">Intel&#8217;s need for</a> a new strategy and CEO.
During the UBS technology conference, Zinsner said he <a target="_blank" href="https://www.benzinga.com/24/12/42344006/intel-interim-co-chief-expects-ceo-to-have-foundry-experience-stands-by-forecast" rel="noreferrer noopener">expects the next</a> chief to be proficient in&nbsp;manufacturing and product&nbsp;development. He reiterated Intel&#8217;s fourth-quarter revenue&nbsp;guidance of $13.30 billion—$14.30 billion versus the analyst consensus of $13.81 billion.
Truist Securities and&nbsp;Benchmark analysts recently flagged that Intel&#8217;s separation of the foundry business could cost the $7.8 billion U.S. chip subsidy.
Price Action: INTC stock traded higher by 0.29% to $20.84 premarket at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42469927/google-has-the-ability-to-scale-ai-by-leveraging-its-global-user-base-analyst" target="_blank" rel="noreferrer noopener">Google Has The Ability To Scale AI By Leveraging Its Global User Base: Analyst</a></li>
</ul>
Photo via Shutterstock

Tech

Media

INTC

NVDA

Intel CFO Hints at Possible Division Split as Company Struggles To Recapture Moat

Stifel analyst Ruben Roy maintains Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) with a Buy and raises the price target from $82 to $95.

CIEN

Stifel Maintains Buy on Ciena, Raises Price Target to $95

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company," "RumbleOn," "we," "us," or "our") today announced the preliminary results of its $10.0 million fully backstopped registered equity rights offering (the "Rights Offering") for shares of the Company's Class B common stock, par value $0.001 per share (the "Class B common stock"). The subscription period for the Rights Offering expired at 5:00 p.m. Eastern Time, on December 12, 2024 (the "Expiration Time"). The Rights Offering resulted in subscriptions to purchase 2,043,011 shares of Class B common stock at a price of $4.18 per share (the "Subscription Price"). The shares of Class B common stock subscribed for are expected to be issued to participating stockholders on or about December 17, 2024.

Offerings

RMBL

RumbleOn Announces Preliminary Results Of $10M Fully Backstopped Registered Rights Offering For Shares Of The Company's Class B Common Stock At A Price Of $4.18 Per Share

Roth MKM analyst Bill Kirk maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Neutral and raises the price target from $755 to $907.

COST

Roth MKM Maintains Neutral on Costco Wholesale, Raises Price Target to $907

Piper Sandler analyst Mark Fitzgibbon maintains Orange County Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBT#NASDAQ">OBT</a>) with a Overweight and raises the price target from $66 to $71.

Piper Sandler Maintains Overweight on Orange County Bancorp, Raises Price Target to $71

Piper Sandler analyst Mark Fitzgibbon maintains Metropolitan Bank Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCB#NYSE">MCB</a>) with a Overweight and raises the price target from $67 to $74.

Piper Sandler Maintains Overweight on Metropolitan Bank Holding, Raises Price Target to $74

The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh in patients with or without prior biologic failure and was the basis for the positive opinion&nbsp;
VIVID-1 was the first pivotal Crohn's disease trial to show benefits in hard-to-treat symptom of bowel urgency using a patient-centric scale
Omvoh will be the first treatment for Crohn's disease with results demonstrating improvements of histologic measures of inflammation included in its label, if approved by the European Commission
Lilly has also submitted Omvoh in the U.S. for approval to treat adults with moderately to severely active Crohn's disease, with a decision expected in the first half of 2025
INDIANAPOLIS, Dec. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Omvoh&#xAE; (mirikizumab), an interleukin-23p19 (IL-23p19) antagonist, for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Biotech

General

Eli Lilly Announces Omvoh Has Been Recommended By EMA's CHMP For Approval In The European Union For Adults With Moderately To Severely Active Crohn's Disease; The Phase 3 VIVID-1 Trial Evaluated The Safety And Efficacy Of Omvoh In Patients With Or Without Prior Biologic Failure And Was The Basis For The Positive Opinion

Piper Sandler analyst Joseph Catanzaro maintains Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) with a Overweight and raises the price target from $7 to $10.

CRDF

Piper Sandler Maintains Overweight on Cardiff Oncology, Raises Price Target to $10

JP Morgan analyst Joseph Greff maintains Travel+Leisure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNL#NYSE">TNL</a>) with a Overweight and raises the price target from $56 to $63.

JP Morgan Maintains Overweight on Travel+Leisure, Raises Price Target to $63

Piper Sandler analyst Jason Bednar maintains NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) with a Overweight and raises the price target from $28 to $42.

NVCR

Piper Sandler Maintains Overweight on NovoCure, Raises Price Target to $42

Oppenheimer analyst Ian Zaffino maintains Knife River Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNF#NYSE">KNF</a>) with a Outperform and raises the price target from $110 to $120.

Oppenheimer Maintains Outperform on Knife River Holding, Raises Price Target to $120

JP Morgan analyst Joseph Greff maintains Marriott Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) with a Neutral and raises the price target from $251 to $269.

Comments

News

Latest news for (IMPNF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga